JP2016518333A5 - - Google Patents

Download PDF

Info

Publication number
JP2016518333A5
JP2016518333A5 JP2016502067A JP2016502067A JP2016518333A5 JP 2016518333 A5 JP2016518333 A5 JP 2016518333A5 JP 2016502067 A JP2016502067 A JP 2016502067A JP 2016502067 A JP2016502067 A JP 2016502067A JP 2016518333 A5 JP2016518333 A5 JP 2016518333A5
Authority
JP
Japan
Prior art keywords
seq
antibody
fragment
nos
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016502067A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016518333A (ja
JP6482524B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/026159 external-priority patent/WO2014151644A2/en
Publication of JP2016518333A publication Critical patent/JP2016518333A/ja
Publication of JP2016518333A5 publication Critical patent/JP2016518333A5/ja
Application granted granted Critical
Publication of JP6482524B2 publication Critical patent/JP6482524B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016502067A 2013-03-15 2014-03-13 抗cd52抗体 Expired - Fee Related JP6482524B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361794576P 2013-03-15 2013-03-15
US61/794,576 2013-03-15
PCT/US2014/026159 WO2014151644A2 (en) 2013-03-15 2014-03-13 Anti-cd52 antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018229547A Division JP2019069960A (ja) 2013-03-15 2018-12-07 抗cd52抗体

Publications (3)

Publication Number Publication Date
JP2016518333A JP2016518333A (ja) 2016-06-23
JP2016518333A5 true JP2016518333A5 (https=) 2017-04-13
JP6482524B2 JP6482524B2 (ja) 2019-03-13

Family

ID=50391542

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016502067A Expired - Fee Related JP6482524B2 (ja) 2013-03-15 2014-03-13 抗cd52抗体
JP2018229547A Pending JP2019069960A (ja) 2013-03-15 2018-12-07 抗cd52抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018229547A Pending JP2019069960A (ja) 2013-03-15 2018-12-07 抗cd52抗体

Country Status (35)

Country Link
US (2) US9708407B2 (https=)
EP (1) EP2970467B1 (https=)
JP (2) JP6482524B2 (https=)
KR (1) KR20150131286A (https=)
CN (1) CN105209495B (https=)
AR (1) AR095199A1 (https=)
AU (1) AU2014233685B2 (https=)
BR (1) BR112015022464A2 (https=)
CA (1) CA2906539A1 (https=)
CL (1) CL2015002705A1 (https=)
CR (1) CR20150547A (https=)
CY (1) CY1121795T1 (https=)
DK (1) DK2970467T3 (https=)
DO (1) DOP2015000211A (https=)
EA (1) EA031730B1 (https=)
ES (1) ES2710976T3 (https=)
GT (1) GT201500267A (https=)
HR (1) HRP20190085T1 (https=)
HU (1) HUE041796T2 (https=)
IL (1) IL241410A0 (https=)
LT (1) LT2970467T (https=)
MA (1) MA38485A1 (https=)
MX (1) MX2015012991A (https=)
NZ (1) NZ631473A (https=)
PE (1) PE20151757A1 (https=)
PH (1) PH12015501932A1 (https=)
PL (1) PL2970467T3 (https=)
PT (1) PT2970467T (https=)
SG (1) SG11201506932SA (https=)
SI (1) SI2970467T1 (https=)
TN (1) TN2015000415A1 (https=)
TR (1) TR201900638T4 (https=)
TW (1) TWI644923B (https=)
UY (1) UY35440A (https=)
WO (1) WO2014151644A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2998405B1 (en) 2009-05-13 2019-12-11 Genzyme Corporation Anti-human cd52 immunoglobulins
CA2761885A1 (en) 2009-05-13 2010-11-18 Genzyme Corporation Methods and compositions for treating lupus
CN110351062B (zh) * 2014-01-28 2022-03-01 华为技术有限公司 数据传输的指示方法、接入点和终端
US20200299399A1 (en) * 2017-04-21 2020-09-24 Genzyme Corporation Treatment of Multiple Sclerosis with Anti-CD52 Antibodies
EP3752193A4 (en) * 2018-02-13 2022-02-23 Merck Sharp & Dohme Corp. METHODS OF TREATMENT OF CANCER WITH ANTI-PD-1 ANTIBODIES AND ANTI-CTLA4 ANTIBODIES
PE20220568A1 (es) 2019-05-21 2022-04-20 Novartis Ag Moleculas de union a cd19 y usos de las mismas
WO2021022044A1 (en) * 2019-07-31 2021-02-04 Forty Seven, Inc. Depletion regimes for engineered t-cell or nk-cell therapy
EP4574840A1 (en) * 2022-08-15 2025-06-25 The University of Tokyo Method for producing immunoglobulin or multimer immunoglobulin using filamentous fungus
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6054561A (en) 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4970198A (en) 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
WO1987006265A1 (fr) 1986-04-17 1987-10-22 Kyowa Hakko Kogyo Co., Ltd. Nouveaux composes dc-88a et dc-89a1, et procede pour leur preparation
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル. モリソン,シェリー ドメイン‐変性不変部を有する抗体
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP2598116B2 (ja) 1988-12-28 1997-04-09 協和醗酵工業株式会社 新規物質dc113
JP2510335B2 (ja) 1989-07-03 1996-06-26 協和醗酵工業株式会社 Dc―88a誘導体
US5187186A (en) 1989-07-03 1993-02-16 Kyowa Hakko Kogyo Co., Ltd. Pyrroloindole derivatives
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
GB9022547D0 (en) 1990-10-17 1990-11-28 Wellcome Found Purified immunoglobulin
GB9108056D0 (en) 1991-04-16 1991-06-05 Hale Geoffrey Synthetic antigen
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5264586A (en) 1991-07-17 1993-11-23 The Scripps Research Institute Analogs of calicheamicin gamma1I, method of making and using the same
US5269388A (en) 1991-11-12 1993-12-14 Stress-Tek, Inc. Weighing bed
GB9125768D0 (en) 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
WO1994026087A2 (en) 1993-05-14 1994-11-24 Connor Kim C O Recombinant protein production and insect cell culture and process
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US7119248B1 (en) 1994-04-12 2006-10-10 Miltenyi Biotec Gmbh Antibodies against epitopes with homology to self antigens, methods of preparation and applications thereof
CA2165819C (en) 1994-04-22 2005-12-27 Nobuyoshi Amishiro Dc-89 derivatives
US5550246A (en) 1994-09-07 1996-08-27 The Scripps Research Institute Calicheamicin mimics
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
WO1998052976A1 (en) 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
US6172213B1 (en) 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
WO2000034317A2 (en) 1998-12-08 2000-06-15 Biovation Limited Method for reducing immunogenicity of proteins
ES2276708T3 (es) 1999-11-24 2007-07-01 Immunogen, Inc. Agentes citotoxicos que comprenden taxanos y su uso terapeutico.
BRPI0108923B8 (pt) 2000-03-03 2021-05-25 Cambridge Antibody Tech Limited elemento de ligação específico, ácido nucleico isolado, célula hospedeira, métodos para produzir um elemento de ligação específico ou domínio vh ou vl de anticorpo, e, para obter um elemento de ligação específico que liga eotaxina
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
US7465790B2 (en) 2000-10-09 2008-12-16 Isis Innovation, Inc. Therapeutic antibodies
US20020132983A1 (en) 2000-11-30 2002-09-19 Junghans Richard P. Antibodies as chimeric effector cell receptors against tumor antigens
CA2467633C (en) 2001-12-03 2012-03-27 Abgenix, Inc. Antibody categorization based on binding characteristics
JP4063769B2 (ja) 2001-12-28 2008-03-19 中外製薬株式会社 タンパク質安定化方法
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
WO2004042032A2 (en) 2002-11-01 2004-05-21 The Ohio State University Research Foundation Cytogenetic abnormalities that are predictive of response to therapy for chronic lymphocytic leukemia
CN1225480C (zh) 2002-12-18 2005-11-02 马菁 抗cd52单克隆抗体、其编码序列及应用
US7534427B2 (en) 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
AU2004226492A1 (en) 2003-03-31 2004-10-14 Kirin Beer Kabushiki Kaisha Method of inducing differentiation and proliferating regulatory T cell by anti-CD52 antibody and medicinal composition therefor
WO2005017149A1 (en) 2003-06-03 2005-02-24 Cell Genesys, Inc. Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
WO2005042581A2 (en) 2003-11-01 2005-05-12 Biovation Ltd. Modified anti-cd52 antibody
US20060204496A1 (en) 2003-11-28 2006-09-14 Tetsuo Kojima Agonist antibody against heteroreceptor
ITRM20030601A1 (it) * 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
US7655229B2 (en) 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
JP2009504136A (ja) 2005-05-24 2009-02-05 アベスタゲン リミテッド 慢性リンパ性白血病治療のためのcd52に対するモノクローナル抗体産生のための組み換え法
DK1888113T3 (da) * 2005-05-27 2014-09-01 Biogen Idec Inc Tweak-bindende antistoffer
WO2007076927A1 (en) 2005-12-30 2007-07-12 Merck Patent Gmbh Anti-il-6 antibodies preventing the binding of il-6 complexed with il-6ralpha to gp130
WO2007121233A1 (en) 2006-04-12 2007-10-25 Genzyme Corporation Methods of treating autoimmune diseases
US9498528B2 (en) 2006-09-13 2016-11-22 Genzyme Corporation Treatment of multiple sclerosis (MS)
KR101583587B1 (ko) 2006-09-13 2016-01-08 젠자임 코포레이션 캠패스-1h에 의한 다발성 경화증 (ms)의 치료
JP5337055B2 (ja) * 2007-02-28 2013-11-06 メルク・シャープ・アンド・ドーム・コーポレーション 免疫性障害の処置のための組合せ治療
US20100178293A1 (en) 2007-06-22 2010-07-15 Olaf Weber Use of antibodies against the cd52 antigen for the treatment of neurological disorders, particularly transmissible spongiform encephalopathy and alzheimer's disease
WO2010132697A2 (en) 2009-05-13 2010-11-18 Genzyme Corporation Methods and compositions for treatment
EP2998405B1 (en) * 2009-05-13 2019-12-11 Genzyme Corporation Anti-human cd52 immunoglobulins
CA2761885A1 (en) 2009-05-13 2010-11-18 Genzyme Corporation Methods and compositions for treating lupus
SI2454284T1 (en) * 2009-07-15 2018-07-31 Aimm Therapeutics B.V. Compounds that specifically bind to Gram-positive bacteria
DK2593594T3 (en) * 2010-07-16 2017-12-11 Adimab Llc ANTIBODY LIBRARIES

Similar Documents

Publication Publication Date Title
JP2016518333A5 (https=)
JP2020525032A5 (https=)
JP2019201643A5 (https=)
JP2018527919A5 (https=)
JP2018532766A5 (https=)
JP2013545455A5 (https=)
JP2013538057A5 (https=)
JP2020510422A5 (https=)
JP2019532619A5 (https=)
JP2017531427A5 (https=)
JP2020508655A5 (https=)
JP2016533763A5 (ja) ヒトpd−1に特異的に結合する抗体抗原結合ドメインおよびそれを含む医薬組成物
HRP20200390T1 (hr) Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma)
JP2018121657A5 (https=)
JP2015163068A5 (https=)
JP2020514277A5 (https=)
JP2018523493A5 (https=)
RU2016100892A (ru) Антитела против tweakr и их применение
JP2014526898A5 (https=)
JP2015525795A5 (https=)
JP2018517431A5 (https=)
JP2017504578A5 (https=)
JP2019527194A5 (https=)
JP2012501670A5 (https=)
JP2012526558A5 (https=)